The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
The facility features 2,176 high-performance GPUs across the US and Europe
The Phase 2 envisionGI study is testing deudomperidone, an experimental drug aimed at treating idiopathic gastroparesis
The initial consideration for the transaction is US$ 12 million
SPARK has extended its influence to an additional 9.47 million students worldwide
The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
The company announced positive topline data from the Phase 3 ADorable-1 trial
Subscribe To Our Newsletter & Stay Updated
